In agreement with these data, others have shown that cDC1s are required for tumor control at both primary and metastatic sites1,18,24,43 Furthermore, cDC1s are required for responses to checkpoint immunotherapy, and increased cDC1 numbers improve the response to chemotherapy in some cancer models2,3,25,26,59. The gene discussed is MPPE1; the disease is neoplasm.